Anika Therapeutics (ANIK) Long-Term Deferred Tax (2010 - 2026)

Anika Therapeutics (ANIK) has 10 years of Long-Term Deferred Tax data on file, last reported at $1.2 million in Q1 2026.

• Long-Term Deferred Tax for Q1 2026 came in at $1.2 million, down 3.2% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.2 million (down 3.2% YoY), and the FY2025 annual result was $1.3 million, up 8.33% from the prior year.
• Long-Term Deferred Tax eased to $1.2 million in Q1 2026 per ANIK's latest filing, from $1.3 million in the prior quarter.
• Over five years, Long-Term Deferred Tax peaked at $1.5 million in Q1 2023 and troughed at $1.2 million in Q1 2026.
• A 5-year average of $1.3 million and a median of $1.3 million in 2024 frame the typical range for Long-Term Deferred Tax.
• The sharpest annual moves came in 2024 and 2025: Long-Term Deferred Tax slipped 20.95% in 2024, then climbed 8.33% in 2025.
• A 5-year view of Long-Term Deferred Tax shows it stood at $1.4 million in 2022, then advanced by 2.76% to $1.5 million in 2023, then slipped by 20.95% to $1.2 million in 2024, then advanced by 8.33% to $1.3 million in 2025, then decreased by 9.8% to $1.2 million in 2026.
• Business Quant data shows ANIK's Long-Term Deferred Tax at $1.2 million in Q1 2026, $1.3 million in Q4 2025, and $1.3 million in Q3 2025.